Whether you’re an emerging manufacturer putting the finishing touches on a new product launch or a small to mid-sized company whose products are outgrowing the post-launch support infrastructure you have in place, Two Labs provides expert consultative services to ensure your product can keep pace with constantly changing market dynamics.
In its simplest form, an order set is like a decision tree for healthcare providers. At the top of the tree are the diagnostics and tests, and based on the results and disease state, physicians can follow specific branches of treatment that best match the patient’s needs, including scans, care procedures, and drugs.
Patient Services have become a must-have for any specialty product launching today. Many pharmaceutical clients are looking to expand their reach and offer enhanced services to their patients, particularly in a competitive landscape.
As the world’s largest single pharmaceutical market, the US should – at least at first glance – provide a simplified pathway for companies looking for a stateside translation of their successes in Europe’s patchwork quilt of countries.
In a world with ever changing needs and demands, especially amongst a global pandemic, issues with the availability of prescription medications continue to challenge the industry.
The main question that sits at the center of the most common licensing questions and obstacles for cell and gene strategies: how do companies license a product that is often never touched by the parties that need to hold the license?
Oncology and other specialty therapies continue to get more and more expensive for payers, placing immense financial pressure on the HCP. The percentage increase in worldwide spending on oncology medications went up by double digits every year between 2013 and 2018, and reached nearly $150 billion in 2018. Modern cancer therapies significantly improve disease outlook, but with a tremendous cost of treatment.
Across the board, wholesalers are moving toward inventory optimization – and that makes sense. They’re holding just enough inventory to match demand projections, opting to stay lean and efficient.
